New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

Up to 5,000 men a year could avoid potentially harmful treatment for prostate cancer if ‘outdated’ guidelines reflected the latest evidence, a charity has said. Closely monitoring the disease with ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...

Thousands of men with prostate cancer will be offered a life-extending drug on the NHS within weeks. For the first time patients whose prostate cancer has not spread will be able to receive the drug ...

Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...